 |
인쇄하기
취소
|
LGCI-Yamanouchi Cooperation for Medicine Development
LGCI announced on November 2 that they have forged a strategic cooperation agreement with Yamanouchi, the third ranking pharmaceutical company in Japan, to develop new medicine for corpulence and hyperlipemia.
According to the agreement, LGCI and Yamanouchi will carry out joint research projects in the next three years, with a possible extension, for the first phase and both companies will c...
According to the agreement, LGCI and Yamanouchi will carry out joint research projects in the next three years, with a possible extension, for the first phase and both companies will c...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.